alexa Mads Hald Andersen
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Mads Hald Andersen

 Department of Hematology, Center for Cancer Immune Therapy, 54P4, Copenhagen University Hospital, Herlev, Herlev Ringvej 75, DK-2730 Herlev, Denmark.

Professor Mads Hald Andersen has just been honored with the Lundbeck Foundation Young Scientist Award, which is awarded to a particularly promising researchers under 40 who have achieved excellent health or scientific research. He had pointed vice-director of CCIT when the centre was established in October 2006. He graduated as M.Sc.Eng. from the Technical University of Denmark (DTU) in 1998. He holds a PhD degree from DTU (2001) and a doctorate in technology (dr. techn; 2006) from the same University. In 2009 he was appointed Honorary Professor at DTU. Before joining CCIT he was Senior Scientist at the Tumor Immunology group at the Danish Cancer Society as well as at the Department of Dermatology, Würzburg University, Germany. In addition, he has founded several minor biotech companies (including SurVac in 2003) and has functioned as scientific advisor in biotech as well as Pharmacy companies.

Research Interest

 His research interests include the characterization of novel tumor antigens, derived from proteins playing an important role for tumor cell growth and/or survival to avoid the selection of antigen-negative tumor cells during immunotherapy; the monitoring and description of T-cell responses in cancer patients both in preclinical and clinical settings.


Influence of Metronomic Cyclophosphamide and Interleukine-2 alone or Combined on Blood Regulatory T Cells in Patients with Advanced Malignant Melanoma Treated with Dendritic Cell Vaccines

Lotte Engell-Noerregaard, Eva Ellebaek, Trine Zeeberg Iversen, Troels Holz Hansen, Marie K Brimnes, ?zcan Met, Jon Bjoern, Mads Hald Andersen, Per thor Straten and Inge Marie Svane

Research Article: J Clin Cell Immunol 2012, 3:118

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version